Xiaofeng Tan, Ph.D.,DeepCovalent, Inc. Discovering New Drugs in a Single Step via GenAI OS3D™, a GenAI framework for de novo drug discovery, reduces early-stage discovery from 2–4 years to ~3 weeks via direct multi-objective molecular generation. The platform achieved 81% re-discovery of 490 FDA-approved drugs and generated GLP-1R candidates with favorable pharmacological profiles versus industry reference compounds, supporting accelerated and higher-success therapeutic discovery. Yi Ni,...

1. 会议介绍 2024年6月8日，第26届SAPE-NE年会在波士顿剑桥万豪酒店隆重举行。本次年会以“Pioneer a New Era of Pharmaceutical Industry with Innovation of Emerging...

1. Introduction SAPA-NE 2024 Annual Meeting On June 8th, 2024, the Sino-American Pharmaceutical Professionals Association–New...